Skip to content | Change text size
 

Dr David CM Kong

Photo of Dr David Kong, Lecturer

Lecturer

BPharm Victorian College of Pharmacy
MPharm Victorian College of Pharmacy
PhD Monash University

Telephone: +61 3 9903 9035
Fax: +61 3 9903 9629
Email: david.kong@pharm.monash.edu.au

Centre for Medicine Use and Safety

Research interests

  • Antimicrobial stewardship and cost-effective use of anti-infectives.
  • Pharmacokinetics and pharmacodynamics of anti-infectives.
  • Optimising anti-infective therapy through alternate route of delivery
  • Pharmacists and medication safety

Education

  • Unit coordinator for Pharmacy Health and Society -1 and 2, Bachelor of Pharmacy
  • Lecturer in clinical pharmacy and pharmacy practice
  • Professional Experiential Placements (PEP)
  • Clinical education for pharmacists

Representative publications

  1. Al-Badriyeh D, Li J, Leung L, Davies G, Stewart K, Kong DCM et.al. Stability of voriconazole eye drops for off-label use in the management of ophthalmic fungal infections. Amer J Health-System Pharmacist. 2009; in-press.
  2. Lau D, Leung L, Fedinands M, Allen P, Fullinfaw R, Kong DCM et.al. Penetration of 1% voriconazole eye drops into human vitreous humour – a prospective, open-label study, Clinical and Experimental Ophthalmology. 2009; in-press.
  3. Al-Badriyeh D, Liew D, Stewart K, Kong DCM. Cost-effectiveness evaluation of voriconazole versus liposomal amphotericin B as empirical therapy for febrile neutropenia in Australia. Journal of Antimicrobial Chemotherapy. 2009; 63(1):197-20.
  4. To TP, Ellis AG, Ching MS, Shilson AD, Kong DCM, Garrett K. Stability of a formulated N-acetylcysteine capsule for the prevention of contrast-induced nephropathy. J Pharm Pract Res. 2008; 38(3):219-222.
  5. Camerino MA, Kong DCM, Chalmers DK, Thompson PE. Solid Phase Synthesis and Circular Dichroism Analysis of (i→i+4) Cyclic Lactam Analogues of Kisspeptin.  Int J Peptide Res Ther. 2008; 14(4):323-331
  6. Stuchbery P, Kong DCM, DeSantis G, Lo SK. Determining Clinical Pharmacy Workload by Patient Disease Classification in Medical and Surgical Patient. J Pharm Pract Res. 2008; 38(2):126-131.
  7. Worth LJ, Blyth CC, Booth DL, Kong DCM, Marriott D, Cassumbohy M, et.al. Optimizing antifungal drug dosing and monitoring to avoid toxicity and improve outcomes in patients with haematological disorders. Internal Medicine Journal. 2008; 38(6b):521-537.
  8. Vuong T, Marriott J, Kong DCM and Siderov J. Implementation of Community Liaison Pharmacy Service. Int J Pharmacy Practice. 2008;16(3):127-135.
  9. Lau D, Fedinands M, Leung L, Fullinfaw R, Kong DCM, Davies G et.al. Penetration of 1% voriconazole eye drops into human aqueous humor – a prospective, open-label study. Arch Ophthalmol.  2008; 126(3):343-346.
  10. Sudhakaran S, Rayner CR, Li J, Kong DCM, Gude NM, Nation RL. Inhibition of P-glycoprotein: Inhibition of Placental P-glycoprotein: Impact on Indinavir Transfer to the Foetus. Brit J Clin Pharm. 2008; 65(5):667-673.
  11. Sudhakaran S, Rayner CR, Li J, Kong DCM, Gude NM Nation RL. Differential Protein Binding of Indinavir and Saquinavir in Matched Maternal and Umbilical Cord Plasma. Brit J Clin Pharm. 2007; 63(3):315-321.
  12. Hassali MA, Kong DCM and Stewart K. A comparison between senior medical students’ and pharmacy pre-registrants’ knowledge and perceptions of generic medicines. Medical Education. 2007; 41:703-710.
  13. George J, Vuong T, Bailey M, Kong DCM, Marriott JM, Stewart K. Development and Validation of the Medication-Based Disease Burden Index. Ann Pharmacotherapy. 2006; 40(4):645-650. 
  14. George J, Kong DCM, Thoman R, Stewart K. Factors Associated with Medication Nonadherence in Patients with COPD. Chest. 2005; 128(5):3198-3204.
  15. Sudhakaran S, Ghabrial H, Nation R, Kong DCM, Gude NM, Angus PW et.al. Differential Bidirectional Transfer of Indinavir in the isolated perfused human placental model. Antimicrobial Agents Chemotherapy. 2005; 49(3):1023-1028.
  16. Levy RW, Rayner CR, Fairley K, Kong DCM, Mijch A, Costello K et.al. Multi-disciplined HIV Adherence Intervention – A Randomised Study.Aids Patient Care And STDS. 2004; 18(12):728-735.
  17. Fairley CK, Levy R, Rayner CR, Allardice K, Kong D et.al.. Randomised trial of an adherence program for clients with HIV. Int J STD and AIDS. 2003; 14:805-809.
  18. Snell G, Kotsimbos TC, Levvey, B, Skiba M, Rutherford DM, Kong DCM, et.al. Pharmacokinetics Assessment of Oral Ganciclovir in Lung Transplant Recipients with Cystic Fibrosis. J Antimicrob Chemothera. 2000; 45:511-516.
  19. Kong DCM, von Iztstein M. The chemoenzymatic synthesis of 9-substituted-3,9-dideoxy-D-glycero-D-galacto-2-nonulosonic acids. Carbohydr Res. 1998; 305: 323-329
  20. Terada T, Kitajima K, Inoue S, Wilson JC, Norton AK, Kong DCM, Thomson RJ et.al. Catalysis by a new sialidase, deaminoneuraminic acid residue-cleaving enzyme (KDNase Sm), initially forms a less stable a-anomer of 3-deoxy-D-glycero-D-galacto-nonulosonic acid and is strongly inhibited by the transition state analog, 2-deoxy-2,3-didehydro-D-glycero-D-galacto-2-nonulopyranosonic acid, but not by 2-deoxy-2,3-didehydro-N-acetylneuraminic acid. J Biol Chem. 1997; 272:5452-5456

External appointments

  • Executive Member, Australian Society for Antimicrobials
  • Member, Australian Commission on Quality and Safety in Health Care’s Antimicrobial Stewardship Advisory Committee
  • Chair, Infectious Diseases Committee of Special Practice for the Society of Hospital Pharmacists of Australia
  • Member, Antimicrobial Subcommittee of the Royal Melbourne Hospital